Texas Medical Center

About: Texas Medical Center is a healthcare organization based out in Houston, Texas, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 2845 authors who have published 2394 publications receiving 79426 citations.

Immunofluorescence studies on sera of patients with breast carcinoma

Abstract: Immunofluorescence studies on sera of patients with breast carcinoma are described. Sera from 42 patients with breast carcinoma 4 with fibrocystic disease and 45 blood bank donors were included in the tests. 31 of the 46 sera revealed positive reactions consisting of faint nucleolar and strong cytoplasmic fluorescence in cells of disease or osteosarcomas. None of the sera reacted with giant cell tumor cells rhabdonyosarcoma cells Levine-3 cell line human embryo kidney culture producing Rauscher leukemia cells normal human embryo cells or human adult skin cells. Control (blood bank donors) sera were negative with the cells of all cultures. Results of absorption studies of the positive sera indicated that the fluorescence reaction may be due to a tumor antigen and not to age blood type number of children treatments familial history of cancer or presence or absence of metastasis.(AUTHORS MODIFIED)

5-Hydroxytryptamine antagonist ICS 205-930 blocks cardiac potassium, sodium and calcium currents.

Abstract: Effects of the 5-hydroxytryptamine receptor antagonist ICS 205-930 [(3 alpha-tropanyl)-1H-indole-3-carboxylic acid ester] on cardiac membrane currents were investigated in single isolated ventricular cells using the whole-cell patch clamp method. Ca++ and K+ currents were studied in guinea pig ventricular cells and Na+ currents were studied in ventricular cells from cultured neonatal rat; these cells are more suitable for Na+ current measurements than are ventricular cells from guinea pig. Under current clamp conditions, ICS 205-930 at 3 x 10(-5) M prolonged the action potential plateau and increased its amplitude of guinea pig cell. The effect was reversible. Increasing the concentration to 3 x 10(-4) M shortened the plateau, reduced its amplitude and depolarized the resting membrane potential. The effects between 10(-7) and 10(-3) M were examined under voltage-clamp conditions. ICS 205-930 produced a concentration-dependent suppression of inwardly rectifying K+ currents with an IC50 of 1.95 x 10(-5) M at a test potential of -40 mV. The effects were time-and voltage-dependent and the IC50 increased to 1.16 x 10(-4) M at -100 mV. The time-dependent outward current and the time-dependent outward tail currents upon repolarization to between -10 and -30 mV also were blocked by the drug in a concentration-dependent manner with IC50 of 3.7 x 10(-5) M. Ca++ currents and Na+ currents also were inhibited in the presence of higher concentration of ICS 205-930 (greater than 10(-4) M), although potency was stronger on Na+ currents. The results show that ICS 205-930 exerts mixed class III and class I antiarrhythmic properties in ventricular myocytes.

Conservation surgery and irradiation as an alternative to mastectomy in the treatment of clinically favorable breast cancer

Abstract: The combination of conservation surgery and radiation therapy for early breast cancer is gaining acceptance as an alternative to radical mastectomy. This article reviews the results of randomized trials showing that there is no advantage to a radical mastectomy in patients with early breast cancer. In addition, the article will review multiple reports concerning the local and regional tumor control and survival of patients treated with conservation surgery and irradiation as well as a comparison of 1073 patients with TIS T1 T2 N0 N1 breast cancer treated at University of Texas (UT) M. D. Anderson Hospital between 1955 and 1980, of whom 345 were treated with conservation surgery and irradiation and 728 were treated with radical or modified radical mastectomy alone. The locoregional recurrence in the patients treated with an intact breast is 4.9%, and 5.6% in patients treated with radical or modified radical mastectomy. There is no significant difference in the 10-year disease-free survival rates between the two groups of patients. In addition, a comparison of 2467 patients with Stage I and Stage II breast cancer treated at the UT M. D. Anderson Hospital shows no significant difference in the incidence of consecutive second breast carcinoma as a result of the use of radiation therapy in the treatment of the first breast cancer.